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Abstract
Background: Chondroitin sulphate is a complex polysaccharide having important structural and protective functions 
in animal tissues. Extracted from animals, this compound is used as a human anti-inflammatory drug. Among bacteria, 
Escherichia coli K4 produces a capsule containing a non-sulphate chondroitin and its development may provide an 
efficient and cheap fermentative production of the polysaccharide.
Results: A random N-methyl-N'-nitro-N-nitrosoguanidine mutagenesis was performed on E. coli K4 to isolate mutants 
showing an increased production of chondroitin. Several mutants were isolated, one of which, here named VZ15, 
produced about 80% more chondroitin than the wild type E. coli. We found that the mutant has a missense mutation in 
the codon 313 of kfoC, the gene encoding chondroitin polymerase (K4CP), with a change from arginine to glutamine. A 
docking analysis to explain the increased productivity of the K4CP enzyme is presented.
Conclusion: The enhanced chondroitin production by the E. coli K4 mutant reported here shows the validity of the 
strain improvement strategy for more cost-friendly fermentative processes in the production of this pharmaceutically 
important but so-far expensive polysaccharide.
Background
Chondroitin sulphate (CS) is a glycosaminoglycan
formed by a repeated disaccharide unit consisting of D-
glucuronic acid (GlcUA) and N-acetyl-D-galactosamine
(GalNAc). The disaccharides are often sulphated in posi-
tion 4 or 6 of the GalNAc, but other sulphation patterns
have also been observed. Human proteoglycans having
CS chains are abundant in cartilage [1], aorta, skeletal
muscle, eye [2], lung [3], and brain [4,5]. They are synthe-
sized intracellularly and secreted to form a macromolec-
ular complex directed to the extracellular matrix or
localized at the cell surface. Biosynthesis of the CS chain
of CS-proteoglycans occurs in the Golgi apparatus [6].
During polymerization, a variety of sulfotransferases [7]
catalyze the sulphation at various positions.
CS can be used as a nutraceutical substance, i.e. nutri-
tional supplement with proven pharmaceutical proper-
ties and efficacy. In fact a number of studies have been
focused on the biochemical activities of orally adminis-
tered exogenous CS [8]. It has been suggested [9] that its
anti-inflammatory and chondro-protective properties
result from an increase in the biosynthesis of connective
tissue components, such as hyaluronic acid, and an
increase of the viscosity of the synovial fluid at disease
sites. Based on meta-analysis of various clinical studies,
CS is presently recommended in Europe as a symptom-
atic slow-acting drug in the treatment of knee osteoar-
thritis (OA). In vitro and in vivo studies have shown that
CS regulates the formation of new cartilage by stimulat-
ing the chondrocyte synthesis of collagen, proteoglycans,
and hyaluronan [10].
Until now extraction of commercial chondroitin sul-
phate from animal tissues has required complex purifica-
tion procedures owing to risks of viral and prionic
contaminations (e.g. extraction from pigs) and high costs,
besides scarcity of row materials due to protection of ani-
mal species under extinction risk (e.g. sharks and chon-
drichthyes). Recently, a growing interest towards the
discovery of novel sources of chondroitin and production
processes has arisen. Some other animal species produce
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CS chains, including squid [11], king crab [12] and
Caenorhabditis elegans [13].
Also bacteria can produce chondroitin chains, although
not sulphated. Indeed, Gram-negative bacteria such as
Escherichia coli K4 contain polysaccharides similar to CS
chains in their capsule. Using this feature to its advantage,
the K4 strain of Escherichia coli promotes its invasiveness
and pathogenicity to host cells by masking its presence
and avoiding antibody response. The K4 capsule contains
a polysaccharide made of chondroitin [GlcUA β(1-3)-
GalNAc β(1-4)]n to which fructose is β-linked at position
C-3 of the GlcUA residue [14]. During synthesis the addi-
tion of fructose branches occurs after the chondroitin
elongation [15]. The enzyme that catalyzes elongation of
the chondroitin chain in E. coli K4 was identified as pro-
tein K4CP, the product of the kfoc gene [16]. However, the
amount of chondroitin produced by K4 is not enough to
allow its use as a potential industrial platform for the pro-
duction of a chondroitin-like polymer. A very recent work
has demonstrated that the quality of carbon source and
growth conditions can greatly affect polysaccharide pro-
duction [17].
In this work we performed an N-methyl-N'-nitro-N-
nitrosoguanidine random mutagenesis to select E. coli K4
mutants that produce an increased amount of the poly-
saccharide and focused our attention on a specific one.
Results and discussion
Random mutagenesis by N-methyl-N'-nitro-N-
nitrosoguanidine
The Escherichia coli K4 chromosome was random-muta-
genized in vivo in order to induce mutations to be
selected for higher production of capsule polysaccharide
(CPS) and, consequently, of chondroitin. In fact, our
hypothesis was that a larger capsule should also contain
higher amounts of K4-chondroitin.
The mutagen used was N-methyl-N'-nitro-N-
nitrosoguanidine (MNNG), whose action is to induce
transitions in DNA molecules. Its working concentration
was 50 μg/ml, allowing 75% survival of bacterial cells.
A f t e r  M N N G  t r e a t m e n t ,  c e l l s  w e r e  p l a t e d  o n  a g a r
medium containing ampicillin and chloramphenicol (2,5
and 3.0 μg/ml respectively, the MIC for wild type K4
when both antibiotics were present). The choice of two
antibiotics was made in order to exclude mutants resis-
tant to a single one, since single resistance could be anti-
biotic-related and not dependent on capsule dimension.
Plates were incubated at 30°C in order to prevent lethality
of temperature-sensitive mutations. Colonies able to
grow on double antibiotic selective medium were consid-
ered as putative candidates to produce a capsule larger
than that of the wild type, which would prevent antibiot-
ics activities [18].
Colorimetric assay with indole-3-acetic-acid
To check the ability of mutants to produce enhanced
amounts of K4-CPS, 100 double-antibiotic resistant colo-
nies, the control strain K4 (wild type) and DH5α (non-
capsulated strain) were tested by a colorimetric assay.
This assay was based on the estimation of colour devel-
oped on plates by colonies following a reaction between
the C3-fructose residue of glucuronic acid and 0.05%
indole-3-acetic acid.
From these experiments we observed that: i) colonies of
the negative control strain DH5α  remained unstained
(data not shown); ii) those of the wild type strain K4
showed a moderately intense violet colour (Fig. 1); iii)
some mutant colonies developed a violet colour distinc-
tively more intense than that of the wild type bacteria
(Fig. 1). Cells from these mutant colonies were consid-
ered as good candidates producers of enhanced amounts
of CPS, and thus chosen for further analyses.
Chondroitin production
Mutants selected from the previous assays were analyzed
for their quantitative CPS production. Cells of the
mutants and of the K4 wild type strain were grown in K4-
medium and after centrifugation their supernatants were
concentrated using centricon filters with 10 kDa cut-off
and analyzed by the carbazole assay followed by capillary
electrophoresis (see Methods).
The carbazole assay showed that 45 mutants had an
enhanced CPS production after 24 hours with respect to
K4 wt strain; mutants showing a minimum of 20% higher
production compared to the wild type were taken under
consideration for further studies. These 15 mutants were
Figure 1 Colorimetric assay. Colorimetric assay of capsule polysac-
charide production performed on wild type E. coli K4 (circled) and 
some of the selected mutants developing an intense colour (arrows).Zanfardino et al. Microbial Cell Factories 2010, 9:34
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subjected to a screening by capillary electrophoresis in
order to quantify the specific chondroitin moiety pro-
duced by each [19].
The wt strain released 0.117 ± g·L-1 of polysaccharide in
the supernatant at the 24th hour of growth while several
mutants showed a slightly higher production. One
mutant, VZ15, released in the medium 0.214 ± 0.005 g·L-1
of K4 polysaccharide after 24 hours, and showed a yield
for polymer on biomass formed significantly higher than
that of the wt strain (0.113 gK4·gcdw
-1 vs. 0.062 gK4·gcdw
-1)
(Fig. 2). The K4-polysaccharide yield value of VZ15 was
82% higher than that reported for the wild type strain.
Thus, the VZ15 mutant was selected as a good over-pro-
ducer strain.
It should be noted that the growth curve of VZ15 was
coincident to that of the wild type (data not shown).
kfoC characterization
Among the possible candidate genes responsible for the
phenotype of CPS over-production in VZ15, we decided
first of all to consider the kfoC gene, which belongs to the
region 2 of the Kps cluster and encodes a protein known
as chondroitin polymerase (K4CP), whose structure has
recently been solved by X-ray crystallography [20]. In
order to understand if the CPS increase in VZ15 was
associated to a mutation in the kfoC gene, we cloned the
kfoC gene of VZ15 in a plasmid vector and sequenced it.
After sequencing we mapped a G to A nucleotide substi-
tution in position 938 of kfoC which corresponds to an
a m i n o  a c i d i c  m i s s e n s e  m u t a t i o n  f r o m  a r g i n i n e  t o  g l u -
tamine at position 313 of K4CP (Fig. 3). We named this
mutation R-313-Q.
To check whether R-313-Q was responsible for the
chondroitin increase in strain VZ15, we transferred a
plasmid bearing either the VZ15 kfoC gene or the wt kfoC
in a "clean" K4 wt background and the two merodiploid
strains were analyzed for their chondroitin production.
Yield (g/gcdw) of the strain carrying extra-copies of the
wt kfoC was 0.162, while that of the isogenic strain carry-
ing the VZ15 kfoC was 0.271. This experiment allowed us
to conclude that mutation R- 313-Q is directly involved in
the increase in chondroitin production in strain VZ15,
regardless from hypothetical additional mutations due to
the MNNG treatment.
Docking analysis of K4CP and its ligands
K4CP is a bi-functional enzyme with two different active
sites: site A1, at the N-terminal domain, adds GalNAc (N-
acetyl-D-galactosamine) units to chondroitin chains,
whereas site A2, at the C-terminal domain, adds GlcUA
(D-glucuronic acid) units [20]. Osawa and co-workers
obtained crystal structures of K4CP in which the A site
was binding either UDP-GalNAc in a catalytically pro-
Figure 2 Polysaccharide production. Yield for K4-polysaccharide on biomass formed by 15 mutants and the wild type K4 strain. Wild type K4 and 
VZ15 mutant are evidenced in blue and red, respectively.
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Figure 3 Amino acidic sequence. 301-330 amino acidic sequence of 
K4CP protein from wild type and VZ15 mutant.
Wt  301 GGEDNEFGYRLYREGCYFRSVEGAMAYHQE 330
VZ15  301 GGEDNEFGYRLYQEGCYFRSVEGAMAYHQE 330Zanfardino et al. Microbial Cell Factories 2010, 9:34
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ductive orientation or UDP-GlcUA in a non-productive
orientation [20]. This finding has suggested that UDP-
GlcUA may act as a regulator/inhibitor of the A1 active
site [20].
Residue Arg-313 is located near the A1 site with the
guanidine moiety at about 7-8 Å from the acetyl moiety
of GalNAc and the carboxyl moiety of GlcUA. Hence,
substitution of the positively charged arginine residue
with a neutral residue, like glutamine, could impair selec-
tively the binding of the negatively charged GlcUA to
active site A1, thus reducing the hypothesized inhibitory
effect of UDP-GlcUA.
In order to verify this hypothesis we docked UDP-Gal-
NAc and UDP-GlcUA to the A1 site of wild type and
mutant K4CPs. The docking analysis showed that Arg-
313 provides a significant direct electrostatic contribu-
tion of -2.5 kcal/mol-1 to the UDP-GlcUA/K4CP binding
energy , that is lost in mutants with neutral residues at
position 313 (Table 1).
An indirect contribution may also derive from the con-
formation of the adjacent residue Arg-268 (Fig. 4). This
residue can adopt a partially bent conformation with the
guanidine moiety close to Asp-311 and Arg-313 (Fig. 4A)
and an extended conformation with the guanidine moiety
at H-bond distance from the carboxyl moiety of GlcUA
(Fig. 4B). In the extended conformation the binding
energy of UDP-GlcUA is considerably higher due to the
stronger interaction between Arg-268 and the carboxy-
late group of glucuronic acid (Fig. 4B). This strong inter-
action and the lower electrostatic repulsion between Arg-
313 and Arg-268 contribute to make the complex UDP-
GlcUA/K4CP with Arg-268 in the extended conforma-
tion about 5 kcal/mol more stable than the same complex
with Arg-268 in the bent conformation.
When Arg-313 is substituted by glutamine, the guani-
dine moiety of Arg-268 forms strong H-bonds with the
carbonyl oxygen of Glu-313 side-chain (Fig. 4C). There-
fore, in this case, the complex with Arg-268 in the bent
conformation (F ig. 4C) is slightly more stable than the
complex with Arg-268 in the extended conformation (Fig.
4D). As a consequence the R-313-Q mutation decreases
the UDP-GlcUA/K4CP interaction energy (LPE) by about
6 kcal/mol (Table 1).
On the contrary, mutation R-313-Q does not impair the
binding of the substrate, GalNAc, as the direct contribu-
tion of Arg-313 to the UDP-GalNAc/K4CP binding
energy is low (about 0.6 kcal/mol). Moreover, the binding
of GalNAc to the A1 active site requires Arg-268 in the
bent conformation (Fig. 4E-F) which is stabilized by Gln-
313. Therefore, the R-313-Q mutation decreases the
UDP-GalNAc/K4CP binding energy by only 1.2 kcal/mol
(Table 1).
Conclusions
Our results indicate that a mutation (R-313-Q) in the
structural gene kfoC for chondroitin polymerase (K4CP)
of E. coli K4 present in mutant VZ15 is responsible for a
significant increase of chondroitin production by this
strain. The docking analysis revealed that the A1 site of
K4CP, binds UDP-GalNAc with an affinity comparable to
that of the wild type K4CP, whereas the UDP-GlcUA
interaction with the mutant A1 site is strongly reduced.
Our data, in addition to providing original information
about the mechanism of K4CP enzyme activity, also
points to mutant VZ15 as a promising tool towards a
cheap and efficient fermentative production of chondroi-
tin for pharmaceutical preparations.
Methods
Materials, medium and microorganisms
Glycerol, ampicillin, IPTG (Isopropyl β-D-1-thiogalacto-
pyranoside) and all the nutrients used to prepare the cul-
t u r e  m e d i u m  w e r e  f r o m  S i g m a  ( S t .  L o u i s ,  M O ,  U S A )
except the soya peptone that was from OXOID (Basing-
stoke, Hampshire, UK). All the reagents and the
glucuronic acid standard used for the carbazole assay as
well as the chemicals used for preparation of running buf-
fer and washing solutions for HPCE (High performance
capillary electrophoresis) analysis were analytical grade
and from Sigma (St. Louis, MO, USA).
The strain used in all experiments was E. coli K4 sero-
type O5:K4:H4 (U141, 11307), a class II microorganism
that is sensitive to ampicillin and kanamycin. It was pur-
chased from the Culture Collection University of Gote-
b o r g  ( G o t e b o r g ,  S w e d e n ) .  W i l d  t y p e  K 4  a n d  m u t a n t s
were stored in 20% glycerol at -80°C.
The growth medium reported by Rodriguez (16) for E.
coli K4 was modified by changing the carbon and nitro-
gen sources in the following manner (K4 medium):10 g·L-
1 of glycerol, 1 g·L-1 of soya peptone, 2 g·L-1 of KH2PO4,
9.7 g·L-1 of K2HPO4, 0.5 g·L-1 of Na3C6H5O7, 1 g·L-1 of
(NH4)2SO4 and 0.1 g·L-1 of MgCl2.
Random mutagenesis by MNNG
MNNG (N-methyl-N'-nitro-N-nitrosoguanidine) was
used at 70 μg/ml, and the procedure was essentially as
follows. Two samples of 2 ml each from an E. coli K4 cul-
ture grown up to 0.4-0.5 O.D. were centrifuged at 6,000 ×
g for 3'. The bacterial pellets were re-suspended in 1 ml of
K4-medium with and without MNNG and the two sus-
pensions were incubated for 1 h at 37°C. Serial dilutions
of treated and untreated (negative control) cells were
plated on medium containing ampicillin (2,5 μg/ml) and
chloramphenicol (3 μg/ml). Plates were incubated at 30°C
to prevent killing of temperature-sensitive mutants.Zanfardino et al. Microbial Cell Factories 2010, 9:34
http://www.microbialcellfactories.com/content/9/1/34
Page 5 of 8
indole-3-acetic acid colorimetric assay
Colonies of wild type and MNNG-induced mutants were
placed onto nitrocellulose filters (Hybond) and incubated
with 0.5% indole-3-acetic acid in ethanol for 10'. Filters
were then placed in a box saturated with vapours gener-
ated by a 36% HCl solution and incubated for 30'. Colour
was developed by reaction of indole-3-acetic acid with
fructose residues linked to GlcUA chondroitin mono-
mers.
Preparation of supernatant samples
K4 polysaccharide production was analysed by carbazole
assay and by capillary electrophoresis. In both cases sam-
ples were collected after an over night growth and centri-
fuged at 1.700 × g (J-20 XP, Beckman Coulter, USA) to
separate the supernatant from cells. Before being analy-
sed, 2 ml of supernatant were ultra-filtered on 10 KDa
centrifugal filter devices (YM-10 Centricon, Millipore,
France), dia-filtered with two volumes of bi-distilled
water and concentrated again to 1/10 of their initial vol-
ume. Samples containing the polysaccharide were then
analysed by carbazole assay or capillary electrophoresis.
Carbazole assay
The glucuronic acid content of the supernatant samples
was tested by the carbazole colorimetric assay according
to the procedure reported by Dubois et al. [21]. Briefly, 5
ml of a 9.5 g/L sodium tetraborate solution in H2SO4 were
added to 1 ml of the samples in glass tubes and put at
100°C for 15 minutes. After cooling, 0.2 ml of a 1.25 g/L
carbazole solution in ethanol were added and tubes were
put again at 100°C for 15 minutes. Sample absorbancies
were measured at 530 nm. Standard solutions of
glucuronic acid in the range from 0.0065 to 0.065 g/L
were prepared to built a calibration curve that was used
to determine the glucuronic acid content of the samples.
The final polysaccharide concentration was obtained
multiplying the uronic acid concentration, obtained by
the carbazole assay, by a fixed numerical factor (2.78) that
takes in consideration the trisaccharide repeated unit
composition of K4 capsular chain.
High performance capillary electrophoresis
Capillary electrophoresis analysis was performed using a
HPCE instrument (P/ACE MDQ; Beckman-Coulter, Palo
Alto, CA, USA), equipped with a deuterium lamp (from
190 to 600 nm wavelength range) and a photo diode array
detector. Runs were performed in electro kinetic mode on
an uncoated fused-silica tube (Beckman Coulter, 50 μm
I.D., 70 cm of total length, 60 cm of effective length) with
an operating buffer containing disodium hydrogen phos-
phate (40 mM), sodium tetra borate (10 mM) and SDS
(40 mM), buffered at pH 9.0 with 1 M HCl, degassed and
filtered through a 0.45 μm membrane.
Table 1: Energy parameters for the model complexes UDP-GlcUA/K4CP, UDP-GlcUA/(R313Q)-K4CP, UDP-GalNAc/K4CP and 
UDP-GalNAc/(R313Q)-K4CP.
Complex Conf. of 
Arg268a
Energy (kcal/mol)
LPEb LEb Ec R268d X313d D311d S334d
K4CP/UDP-GlcUAe ext.a -102.8 -64.1 -5.4 -12.7 -2.5 2.2 -0.8
benta -99.3 -64.0 -8.7 -2.5 2.0 -2.0
(R313Q)/UDP-GlcUAe ext. -100.6 -63.8 +1.3 -12.6 0.14 2.0 -1.4
bent -96.5 -63.9 -8.0 0.21 1.8 -1.9
K4CP/UDP-GalNAc 
(R313Q)/UDP-GalNAc
bent -100.6 -71.5 n.a.f -4.3 -0.64 0.55 -0.72
bent -99.4 -71.5 n.a.f -3.7 ~0 0.59 -0.72
a Conformation of Arg-268: extended (ext.), χ1 = 61°, χ2 = -165°, χ3 = 176°, χ4 = -163°; bent, χ1 = 55°, χ2 = 175°, χ3 = 168°, χ4 = -86°.
b LPE and LE are, respectively, the ligand/protein interaction energy and the ligand internal energy (including torsional energy and van der Waals 
and electrostatic interactions among ligand atoms).
c Difference between the total energy of the complex with Arg-268 in the extended conformation and the total energy of the complex with Arg-
268 in the bent conformation.
d Contributions of single residues to LPE.
e The energy parameters of the most stable form of each complex are shown in bold.
f n.a., not applicable.Zanfardino et al. Microbial Cell Factories 2010, 9:34
http://www.microbialcellfactories.com/content/9/1/34
Page 6 of 8
Figure 4 Docking analysis. Model complexes UDP-GlcUA/K4CP with Arg-268 in the bent (A) and the extended (B) conformation, UDP-GlcUA/
(R313Q)-K4CP with Arg-268 in the bent (C) and the extended (D) conformation, UDP-GalNAc/K4CP (E), and UDP-GalNAc/(R313Q)-K4CP (F). Carbon 
atoms are colored green, nitrogen atoms blue, oxygen atoms red, phosphorus atoms orange, magnesium ion cyan and hydrogen atoms white. For 
clarity, only polar hydrogen atoms are shown. H-bonds are shown as yellow dashed lines, whereas other distances are shown as blue dashed lines. 
Distances are in Å.
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The K4 polysaccharide in the supernatants of shaking
flask microbial growths was detected and quantified
according to the analytical method, already described
[22].
A 60 nL sample total volume, calculated with the Pois-
seuille equation, was automatically injected, operating in
pressure mode for 10 seconds at 1.0 psi, and separations
were performed at 25°C, in normal polarity mode apply-
ing 20 kV for 30 minutes; the analytes were detected at
190 nm. Sample peak areas were recorded and calculated
using the Beckman-Coulter 32 Karat Software while sam-
ple concentrations were determined substituting the
areas values in the K4 calibration curves. The method
s h o w e d  a n  h i g h  l i n e a r i t y  i n  t h e  r a n g e  f r o m  0 . 1  t o  3 . 5
ng·nl-1 for the K4 polysaccharide.
Polymerase chain reaction (PCR) and cloning
kfoC (~2100 bp) amplification was performed by poly-
merase chain reaction (PCR) using chromosomal DNA of
E. coli K4 as template and KfoC-Forward (5'-cgatataca-
gaacaatacg-3') and KfoC-Reverse (5'-gccgggcaacaaggga-
gaccg-3') as primers.
Primers were designed according to the nucleotide
sequence of E. coli K4, available in gene bank (AB079602).
Reaction mixture was made up of: chromosomal DNA
(50 ng); primers F e R (5 μM both); dNTP (0.2 mM); PCR
buffer 1× (Invitrogen); MgCl2 (1.5 mM); Taq DNA poly-
merase 5 U (Invitrogen); The PCR programme was as fol-
lows: 5' at 96°C, than 30 cycles consisting of 45" at 94°C, 1'
at 55°C and 3' at 72°C.
PCR product was cloned into plasmidic vector pGEM-
t-Easy to perform the sequence analysis (CRIBI, Padova).
pETBlue-1 vector was used to generate the merodiploid
K4 derived strains containing extra copies of VZ15 kfoC
and wt kfoC  transcribed under the control of tet  pro-
moter.
Modelling of substrates into the active site of K4CP
Substrates were docked into the active site of K4CP using
the Monte Carlo Energy Minimization strategy. The
ZMM-MVM molecular modelling package (ZMM Soft-
ware Inc.; http://www.zmmsoft.com) [23] was used for all
calculations. Atom-atom interactions were calculated
using the AMBER force field [24] with a cut-off distance
of 8 Å and a relative dielectric constant = 4. Energy calcu-
lations included van der Waals, electrostatic, H-bonds,
and torsion components. Hydration component was not
included. The "Zl" module of ZMM was used to optimize
the geometry of substrates and to attribute partial
charges. X-ray structures of K4CP bound to UDP-GlcUA
and UDP-GalNAc (pdb codes: 2Z86 and 2Z87) were used
to build the initial model complexes. To reduce computa-
tional time a double-shell model of the enzyme was built.
The inner shell included all the residues with at least one
side-chain atom at less than 13 Å from UDP-GalNAc or
UDP-GlcUA. During energy calculation procedures all
the torsion angles of these residues were allowed to vary.
The outer shell included all the residues with at least one
side-chain atom at less than 22 Å from UDP-GalNAc or
UDP-GlcUA. During energy calculation procedures the
torsion angles of the outer shell residues were not allowed
to vary. The metal cofactor was modelled as a Mg2+ ion
with a single water molecule bound at the apical position
of a square pyramid as observed in the crystal structures
of K4CP. The "atom/atom-distance constraint", available
in ZMM, was used to fix the distances between the Mg2+
ion and the surrounding atoms, including the water mol-
ecule, the oxygen atoms of the phosphates of the UDP
moiety, the atoms of the imidazole ring of His-386 and
the carboxylate of Asp-241. A force constant of 1000 kcal/
mol/Å was used. Complexes with total energy up to 5
kcal/mol higher than the lowest-energy complex were
stored for the analysis of energetic contributions. Total
energy was partitioned into intra-receptor, intra-ligand
(LE in Table 1), receptor/ligand (LPE in Table 1) and
energies of the constraints. Receptor/ligand energy was
further partitioned into van der Waals, electrostatic, and
H-bonds components. Moreover, receptor/ligand energy
was also partitioned (i) per active site residue in order to
evaluate the contribution of each residue to the binding
of ligands (the last four columns in Table 1), and (ii) per
ligand atoms. The pdb files of the initial complexes, and
the ZMM instruction files containing the list of mobile
residues, constrains and parameters used during calcula-
tions are available on request.
The PyMOL software (DeLano Scientific LLC) was
used to visualize structures and to prepare figures of the
complexes.
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